---
document_datetime: 2023-09-21 17:08:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/mavenclad-epar-all-authorised-presentations_en.pdf
document_name: mavenclad-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0598244
conversion_datetime: 2025-12-26 11:48:44.984779
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/17/1212/001 | Mavenclad         | 10 mg      | Tablet                | Oral use                  | blister (alu/alu)     | 1 tablet    |
| EU/1/17/1212/002 | Mavenclad         | 10 mg      | Tablet                | Oral use                  | blister (alu/alu)     | 4 tablets   |
| EU/1/17/1212/003 | Mavenclad         | 10 mg      | Tablet                | Oral use                  | blister (alu/alu)     | 5 tablets   |
| EU/1/17/1212/004 | Mavenclad         | 10 mg      | Tablet                | Oral use                  | blister (alu/alu)     | 6 tablets   |
| EU/1/17/1212/005 | Mavenclad         | 10 mg      | Tablet                | Oral use                  | blister (alu/alu)     | 7 tablets   |
| EU/1/17/1212/006 | Mavenclad         | 10 mg      | Tablet                | Oral use                  | blister (alu/alu)     | 8 tablets   |